Johnson & Johnson's Q3 2023: $21.3B Rise In Sales, 'Sharpened Focus' On Innovation & Biotech Solutions
Johnson & Johnson's Q3 2023: $21.3B Rise In Sales, 'Sharpened Focus' On Innovation & Biotech Solutions
Healthcare company Johnson & Johnson (J&J) (NYSE:JNJ) shared its financial outcomes for the third quarter of 2023, reflecting:
医疗保健公司 强生（强生） 纽约证券交易所代码：JNJ）分享了其财务业绩 2023 年第三季度， 反映：
-
Total reported sales of $21,351 million, a 6.8% increase compared to the same period in 2022. Of which U.S. sales totaled $11,996 million (11.1% increase from 2022's comparable period), and the rest of the world $9,355 million (1.6% increase from 2022's same period.)
-
In terms of segments, reported sales owe 65.0% to Innovate Medicine ($13,893 million, a 5.1% growth from 2022's same period); and 34.9% to MedTech ($7,458 million, a 10.0% growth from 2022's same period.)
-
In terms of psychedelics, these numbers involve Spratavo (S-ketamine) sales for a total of $154 million in the U.S., a 75% increase compared to 2022's same quarter and $29 million in the rest of the world.
-
报告的销售总额 在213.51亿美元中，a 增长 6.8% 与2022年同期相比。其中 美国的销售总额为119.96亿美元 （比2022年同期增长11.1％），世界其他地区为93.55亿美元（比2022年同期增长1.6％）。
-
就细分市场而言，已报告 销售额欠创新医学65.0％ （138.93亿美元，比2022年同期增长5.1％）； 34.9% 流向医疗科技 （74.58亿美元，比2022年同期增长10.0％。）
-
在迷幻药方面，这些数字涉及 Spratavo（s-ketamine）的销量 在美国的总收入为1.54亿美元，与2022年同期相比增长了75％，在世界其他地区增长了2900万美元。
See Also: Sales Of Johnson & Johnson Esketamine Drug Spravato Rise Nearly 100% Year Over Year
另见：强生公司埃西胺酮药物 Spravato 的销量同比增长近 100%
-
Net earnings of $4,309 million, slightly behind 2022's comparable period of $4,310 million. Yet earnings per share (diluted) increased 4.3% from period to period from $1.62 in 2022 to $1.69 in 2023.
-
The cost of products sold was $6,606 million vs. $6,172 million in the same 2022 period.
-
R&D expenses totaled $3,447 million, vs. $3,485 million in the same 2022 period.
-
Selling, marketing and administrative expenses for a total $5,400 million, an 8% increase from 2022 ($4,975 million.)
-
净收益为43.09亿美元，略低于2022年同期的43.1亿美元。然而，每股收益（摊薄）同比增长4.3％，从2022年的1.62美元增至2023年的1.69美元。
-
所售产品的成本 为66.06亿美元，而2022年同期为61.72亿美元。
-
研发费用 总额为34.47亿美元，而2022年同期为34.85亿美元。
-
销售、营销和管理费用总额为54亿美元，比2022年（49.75亿美元）增长8％。
The quarter also saw a one-time, non-cash gain of around $21 billion, related to the final separation of J&J's consumer health business and considered as part of its discontinued operations.
本季度还出现了 一次性非现金收益约为210亿美元，与强生消费者健康业务的最终分离有关，被视为其已终止业务的一部分。
Pipeline, Programs & IP
管道、项目和知识产权
On the regulatory front, J&J received several treatment approvals from the FDA and the European Commission (2). Additionally, it submitted two applications to the European Medicines Agency, and another supplemental New Drug Application (NDA) to the FDA.
在 监管方面，强生获得了多项治疗批准 食品药品管理局 和 欧盟委员会 (2)。此外，它还向该委员会提交了两份申请 欧洲药品管理局，以及美国食品和药物管理局的另一项补充新药申请（NDA）。
The company also released data on several different development programs, around the multi-targeting bispecific monoclonal antibody RYBREVANT. It as launched the OPTRELL catheter for the mapping of complex cardiac arrhythmias.
该公司还发布了围绕多靶向双特异性单克隆抗体RYBREVANT的几个不同开发项目的数据。它刚刚推出 OPTRELL 导管 用于绘制复杂心律失常的地图。
CEO and board chairman Joaquin Duato said the quarter's "strong results" along with "significant pipeline advances" altogether provide "a solid foundation for future sustained growth."
首席执行官兼董事会主席华金·杜阿托 表示，本季度的 “强劲业绩” 以及 “重大产品线进展” 为 “未来的持续增长奠定了坚实的基础”。
"With a sharpened focus on Innovative Medicine and MedTech solutions, Johnson & Johnson is innovating across the spectrum of healthcare and is poised to deliver the medical breakthroughs of tomorrow," Duato added.
杜阿托补充说：“强生公司更加关注创新医学和医疗技术解决方案，正在医疗保健领域进行创新，并有望实现未来的医学突破。”
See full financial results, business collaborations and earnings presentation here.
在此处查看完整的财务业绩、业务合作和收益报告。
Photo: Benzinga edit with photo by Commons and Pexels.
照片：Benzinga 编辑，照片由 Commons 和 Pexels 拍摄。